ooo30 Prospective Validation of a Novel Visual Analogue Uroflowmetry Score (VAUS) in Men With Lower Urinary Tract Symptoms(LUTS): Our Early Experience.

Raj Tiwari, Henry Ho, Ng Mei Ying Singapore General Hospital

Aims: Family physicians are increasingly involved in care of patients with LUTS, however are limited by lack of tools to monitor disease progression. VAUS provides a cost effective, easily administered non - invasive tool help them play a larger role. Many other visual prostate scores have already been validated internationally especially in less literate elderly patients. Our primary aim was to validate VAUS when correlated with uroflowmetry measured maximal flow rate (Qmax). Secondary aim was to study the correlation between age, Qmax and VAUS scores.

Methodology: After IRB approval, 117 patients were prospectively recruited. They had VAUS scores and uroflowmetry performed. VAUS is a novel 5 point visual analogue scoring of urine flow, with 1 being the weakest and 5 the strongest (diagram 1). Data was analysed using SPSS where spearman's correlation coefficient and Mann - Whitney U test was performed looking for significance.

Result: 117 patients were studied with mean age of 66.94(20 - 90). Mean Qmax was 14.2 (4.3 - 44.8) ml/s and median VAUS score was 3(1 - 5). VAUS and Qmax showed good correlation with p value of 0.015. Qmax and age showed good correlation with p value of 0.016 however VAUS and age were not correlated significantly with p value of 0.54. Comparison of VAUS scores between group above and below 66 years showed no significant differences.

Conclusion: VAUS is a promising tool for monitoring of lower urinary tract symptoms in our patients showing significant correlation with uroflowmetry. Further larger studies will follow to better define patient group benefiting most from it.